Lung Cancer Treatment News
Understanding Adjuvant Therapy
Learn the differences between neoadjuvant, adjuvant, and peri-adjuvant therapies, and how treatment decisions are made.
Together we can make a lasting impact
Your support is vital to our mission of funding transformative science and improving survivorship.
Recently diagnosed with lung cancer?
Learn more about your lung cancer diagnosis. What questions should you be asking? What are the most important next steps? Know that you have options and remember that knowledge is power.
Meet the Researchers
View All-
Julie Wu, MD
Staff Physician, Medical Oncology
Precision oncology integrating evidence-based models into clinical practice to personalize treatment approaches
-
Aparna Sharma, DM
Thoracic medical oncologist
Genomic characterization of young onset lung adenocarcinoma
-
Jonathan Villena-Vargas, MD
Thoracic Surgeon
Characterizing T cell PD-1 response in the tumor-draining lymph nodes of early-stage NSCLC patients
-
Research is HOPE. Research will hopefully have me sitting here in #GiveMe20. Give me 20 years post-diagnosis.
Brandi Bryant, living with lung cancer
-
Your generosity is shaping future leaders in lung cancer research.
Kim Norris, Co-Founder and President
-
There is such tremendous hope for all patients with lung cancer right now.
Dr. Christine Lovly, LCFA Young Investigator
Stay Connected
Hope, Research, and Impact in Your Inbox
Join our community and receive monthly updates on inspiring stories, groundbreaking research, and the early career researchers you’re helping to support. Sign up now to be part of the lung cancer fight!
Word of the Day
VEGFR2
VEGFR2, or Vascular Endothelial Growth Factor Receptor 2, is a protein found on the surface of cells that line blood vessels. It plays a critical role in angiogenesis, the process of forming new blood vessels. In lung cancer, targeting VEGFR2 with specific inhibitors can help disrupt the blood supply to tumors, inhibiting their growth and spread.